The sweeping reform brought about by the AIA includes the FITF patent system, which places a premium on maintaining confidentiality, and speed and efficiency in filing patent applications while juggling the uncertainties and nuances of this new system.
Until the interpretation of the rules becomes clearer, companies are best advised to keep their eyes on the ball, says Kenley Hoover.
The implementation of the first-inventor-to-file (FITF) provisions of the Leahy-Smith America Invents Act (AIA) on March 16, 2013, marked the completion of the most radical and sweeping reform to the US patent system in more than 60 years. Changes under the new law have significant implications for the biotechnology industry, which relies heavily on patent rights as crucial value drivers for attracting funding, partnering and protecting its discoveries.
As such, biotechnology innovators must modify their patent strategies to adapt to the new law or risk losing potentially crucial patent rights. This article provides practical suggestions for operational modifi cations in adapting to a FITF system.
You need a subscription to continue reading this content.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
biopharma, first inventor to file, AIA, AIACorp